First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Slomovitz BM, Zhu J, Yin R, Backes F, Bidziński M, Gilbert L, Willmott LJ, Hasegawa K, Kim JW, Kroep JR, Romero I, Gultekin M, Wang PH, Baron-Hay S, Klát J, Rosengarten O, Polignano M, Berrios M, Cadoo K, Lassus H, Maćkowiak-Matejczyk B, Lorusso D, Reyners AKL, Burton ER, Makker V, Yao L, Meng R, Orlowski R, Pignata S

Open source

DOI: 10.1016/s0140-6736(26)02095-7
Published: 2026 Oct 26
Container: Lancet (London, England)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0140-6736-26-02095-7,
  title = {First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.},
  author = {Slomovitz BM and Zhu J and Yin R and Backes F and Bidziński M and Gilbert L and Willmott LJ and Hasegawa K and Kim JW and Kroep JR and Romero I and Gultekin M and Wang PH and Baron-Hay S and Klát J and Rosengarten O and Polignano M and Berrios M and Cadoo K and Lassus H and Maćkowiak-Matejczyk B and Lorusso D and Reyners AKL and Burton ER and Makker V and Yao L and Meng R and Orlowski R and Pignata S},
  year = {2026},
  journal = {Lancet (London, England)},
  doi = {10.1016/s0140-6736(26)02095-7},
  url = {https://doi.org/10.1016/s0140-6736(26)02095-7}
}

RIS

TY  - JOUR
TI  - First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.
AU  - Slomovitz BM
AU  - Zhu J
AU  - Yin R
AU  - Backes F
AU  - Bidziński M
AU  - Gilbert L
AU  - Willmott LJ
AU  - Hasegawa K
AU  - Kim JW
AU  - Kroep JR
AU  - Romero I
AU  - Gultekin M
AU  - Wang PH
AU  - Baron-Hay S
AU  - Klát J
AU  - Rosengarten O
AU  - Polignano M
AU  - Berrios M
AU  - Cadoo K
AU  - Lassus H
AU  - Maćkowiak-Matejczyk B
AU  - Lorusso D
AU  - Reyners AKL
AU  - Burton ER
AU  - Makker V
AU  - Yao L
AU  - Meng R
AU  - Orlowski R
AU  - Pignata S
PY  - 2026
JO  - Lancet (London, England)
DO  - 10.1016/s0140-6736(26)02095-7
UR  - https://doi.org/10.1016/s0140-6736(26)02095-7
ER  -

APA

BM, S., J, Z., R, Y., F, B., M, B., L, G., LJ, W., K, H., JW, K., JR, K., I, R., M, G., PH, W., S, B., J, K., O, R., M, P., M, B., K, C., H, L., B, M., D, L., AKL, R., ER, B., V, M., L, Y., R, M., R, O., & S, P. (2026). First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(26)02095-7

Source records

pubmed · retrieved 2026-11-10T13:13:06.523Z